Acadia Pharmaceuticals Surpasses Billion-Dollar Revenue Milestone in 2025, Beats Q4 Earnings Estimates
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) reported its fourth quarter and full-year 2025 financial results after the market close on Wednesday, delivering a mixed performance against analyst expectations. The company, a biopharmaceutical firm focused on central nervous system disorders, announced it had surpassed $1 billion in annual revenue for the first time in its history.
Earnings and Revenue Performance Versus Estimates
For the critical fourth quarter, Acadia's financial results presented a nuanced picture when compared to Wall Street forecasts. The company reported GAAP total revenues of $284.0 million for Q4 2025. This figure came in below the analyst consensus estimate of approximately $298.3 million. However, this headline GAAP number was significantly impacted by a one-time, non-recurring accounting adjustment related to Inflation Reduction Act (IRA) rebates for its drug NUPLAZID.
Management emphasized an alternative non-GAAP adjusted revenue figure of $298.2 million, which excludes the $20.1 million IRA-related charge and reallocates it across prior periods. On this adjusted basis, which the company states provides a clearer view of underlying commercial performance, revenues slightly exceeded the consensus estimate.
The earnings per share (EPS) story was more straightforwardly positive. Acadia reported a GAAP net income of $274 million, or $1.60 per diluted share, for the quarter. This was heavily boosted by a non-cash income tax benefit of $250 million related to the release of a valuation allowance on deferred tax assets. On a non-GAAP basis, which analysts typically track for operational performance, the company's results also surpassed expectations. The reported non-GAAP EPS was $0.16, edging out the analyst estimate of $0.1356.
Market Reaction and Price Action
The initial market reaction following the earnings release was decisively positive. In after-hours trading, ACAD shares climbed approximately 4.1%. This upward move suggests investors are focusing on the underlying strength of the business—notably the EPS beat and the milestone of crossing $1 billion in annual sales—rather than the GAAP revenue miss attributed to a one-time accounting item. The stock had been relatively flat over the past week and month, indicating the earnings report served as a significant catalyst.
Key Highlights from the 2025 Report
Beyond the quarterly figures, Acadia's full-year 2025 results and strategic updates formed the core of the announcement:
- Record Annual Revenue: The company achieved full-year 2025 GAAP total revenues of $1.07 billion, marking its first year above the billion-dollar threshold. On a non-GAAP adjusted basis, full-year revenues were $1.08 billion, representing 14% year-over-year growth.
- Product Sales Breakdown:
- NUPLAZID (for Parkinson’s disease psychosis): Reported GAAP net sales of $680.1 million for the year. On a non-GAAP adjusted basis, which management prefers for comparison, sales were $691.9 million, up 15% year-over-year. The company highlighted strong underlying volume growth of 9% for the full year.
- DAYBUE (for Rett syndrome): Net product sales reached $391.4 million for the full year, a 12% increase over 2024. Fourth-quarter sales of $110 million grew 13% year-over-year.
- Strategic and Pipeline Updates: The company is preparing for a full commercial launch of a new powder formulation, DAYBUE STIX, in early Q2 2026. It has also completed a 30% expansion of its NUPLAZID sales force. A key near-term catalyst is the Phase 2 RADIANT study of remlifanserin for Alzheimer’s disease psychosis, with top-line results expected between August and October 2026.
- 2026 Financial Guidance: Acadia provided its first full-year outlook for 2026, projecting:
- Total revenues between $1.22 billion and $1.28 billion.
- NUPLAZID net sales of $760-$790 million.
- DAYBUE net sales of $460-$490 million.
- Notably, the midpoint of the total revenue guidance range ($1.25 billion) sits above the current analyst consensus estimate of $1.227 billion for the year.
Conclusion
Acadia Pharmaceuticals closed a landmark 2025 by cementing its transition into a commercial-stage company with over a billion dollars in revenue. While a one-time IRA rebate adjustment muddied the Q4 GAAP revenue picture, the underlying business showed strength with an EPS beat and continued double-digit growth for its two flagship products. The market's positive after-hours reaction appears to validate management's focus on operational performance and future growth, further supported by 2026 revenue guidance that exceeds current Street expectations. The company's balance sheet remains robust with $820 million in cash and investments, providing ample fuel for its commercial expansions and mid-stage pipeline development.
For a detailed breakdown of future earnings estimates and historical performance, you can review more data on ACADIA PHARMACEUTICALS INC's earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an endorsement, or a recommendation to buy, sell, or hold any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
